BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33955826)

  • 21. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
    Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
    Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
    Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
    BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy.
    Chen R; Wu J; Liu S; Sun Y; Liu G; Zhang L; Yu Q; Xu J; Meng L
    Medicine (Baltimore); 2023 Aug; 102(34):e34786. PubMed ID: 37653791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
    Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
    Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
    Smith CC; Beckermann KE; Bortone DS; De Cubas AA; Bixby LM; Lee SJ; Panda A; Ganesan S; Bhanot G; Wallen EM; Milowsky MI; Kim WY; Rathmell WK; Swanstrom R; Parker JS; Serody JS; Selitsky SR; Vincent BG
    J Clin Invest; 2018 Nov; 128(11):4804-4820. PubMed ID: 30137025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
    Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
    BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of an independent immune-genes prognostic index for renal cell carcinoma.
    Li G; Wei X; Su S; Wang S; Wang W; Wang Y; Meng X; Xia J; Song N; Qin C
    BMC Cancer; 2021 Jun; 21(1):746. PubMed ID: 34187413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
    Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
    Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.
    Zhang X; Zhang M; Song L; Wang S; Wei X; Shao W; Song N
    Sci Rep; 2023 Nov; 13(1):20266. PubMed ID: 37985807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC).
    Liu S; Li S; Wang Y; Wang F; Zhang L; Xian S; Yang D; Yuan M; Dai F; Zhao X; Liu Y; Jin Y; Zeng Z; Mahgoub OKA; Zhou C; Cheng Y
    J Cell Biochem; 2020 Mar; 121(3):2571-2581. PubMed ID: 31823423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
    Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Jun; 36(6):e24409. PubMed ID: 35441741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.